ASGCT and FDA will host a virtual scientific workshop over two half days. This free, public event will explore key immunology-related topics that have implications across the class of AAV gene therapies, including immune responses, antibody testing, and redosing strategies. The workshop will provide valuable insights for professionals in both academia and industry as it addresses pressing challenges in AAV gene therapies and new approaches.

Register at: https://www.asgct.org/asgct-events/january-2025/class-considerations-on-immunogenicity-for-aav-gen